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Background:  Carnitine is a key molecule for mitochondrial fatty acid β-oxidation, and previous reports have suggested beneficial effects 
of carnitine administration on heart failure (HF) patients. However, little is known about the change of systemic carnitine homeostasis in HF 
patients.
methods:  We measured serum concentrations of free carnitine and acylcarnitine in patients with acute decompensated HF (ADHF) or 
stable-HF as well as those without HF (non-HF).
results:  Thirty-one ADHF, 26 stable-HF and 26 non-HF patients were randomly enrolled. Serum acylcarnitine was significantly increased 
in ADHF patients (17.3±9.2 μM) compared with stable-HF (13.0±4.4 μM, P<0.05) and non-HF (11.6±3.0 μM, P<0.01) patients, while free 
carnitine was comparable (51.4±14.5 μM in ADHF, 53.4±11.9 μM in stable-HF, and 51.6±10.8 μM in non-HF patients). In stable-HF and 
non-HF patients, serum acylcarnitine was correlated with serum creatinine (r=0.60 and 0.46, P<0.01 and <0.05, respectively). In contrast, 
among ADHF patients the elevation of serum acylcarnitine was independent of serum creatinine (r=-0.01, P=0.95), and was significantly 
correlated with serum total bilirubin (r=0.56, P<0.01). Furthermore, in ADHF patients serum acylcarnitine concentration was significantly 
lowered at the time of their discharge (18.7±9.7 μM on admission to 11.7±5.7 μM at the time of discharge, P<0.01), and the amount of 
change in acylcarnitine concentration was significantly correlated with that in serum total bilirubin (r=0.62, P<0.01).
conclusion:  In stable-HF and non-HF patients, serum acylcarnitine was considered to be accumulated as a consequence of impaired 
glomerular filtration. However, in ADHF patients serum acylcarnitine was elevated, which was not associated with renal dysfunction but with 
liver dysfunction, and it reversibly decreased with the improvement of HF. These results suggested that impaired β-oxidation in the liver 
caused the change of systemic carnitine homeostasis in ADHF state.
